Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

876
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

821
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

813
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
813
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

753
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
753
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.

PLoS computational biology·2026
Same author

Changes in estimands and prevalence of discrepancies in conclusions under the two-trial paradigm: a systematic review.

Journal of clinical epidemiology·2026
Same author

Time to diagnosis and treatment of obstructive sleep apnoea using mandibular jaw movement monitoring versus polysomnography: an open-label, multicentre, randomised, controlled trial.

The Lancet regional health. Europe·2026
Same author

Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.

Nature·2026
Same author

Influence of tacrolimus concentration-to-dose ratio on CLAD risk in lung transplant recipients.

Transplant immunology·2026
Same author

[Assessing the risk-benefit balance of medicines: Some lessons from Covid-19].

Medecine sciences : M/S·2026

Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K

Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study.

Dimitrios Baltzis1, Jody R Dushay1, Jordan Loader1

  • 1Microcirculatory Laboratory and Rongxiang Xu, MD, Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115.

The Journal of Clinical Endocrinology and Metabolism
|September 2, 2016
PubMed
Summary

Linagliptin may improve microvascular function and reduce inflammation in type 2 diabetes patients. This study found improvements in neurovascular function and decreased inflammatory markers with linagliptin treatment.

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.8K
Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling
16:43

Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling

Published on: March 3, 2013

12.8K

Related Experiment Videos

Last Updated: Mar 15, 2026

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

1.0K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.8K
Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling
16:43

Murine Spinotrapezius Model to Assess the Impact of Arteriolar Ligation on Microvascular Function and Remodeling

Published on: March 3, 2013

12.8K

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Metabolic Diseases

Background:

  • Linagliptin, a dipeptidyl peptidase-4 inhibitor, exhibits anti-inflammatory and vasodilatory effects in preclinical models.
  • Its impact on human vascular function, beyond glucose lowering, requires further investigation.
  • Clinical trials are ongoing to assess cardiovascular outcomes associated with linagliptin.

Purpose of the Study:

  • To evaluate the effects of linagliptin on vascular and mitochondrial function surrogates in patients with type 2 diabetes.
  • To assess changes in microvascular and macrovascular reactivity.
  • To investigate the impact on inflammatory markers and endothelial progenitor cells.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 40 type 2 diabetes patients over 12 weeks.
  • Linagliptin (5mg/d) or placebo was administered.
  • Vascular function assessed via laser Doppler iontophoresis and brachial flow-mediated dilation; mitochondrial function by magnetic resonance spectroscopy; inflammatory markers and endothelial cells quantified.

Main Results:

  • Linagliptin treatment increased axon reflex-dependent vasodilation, a marker of neurovascular function (P = .05).
  • A trend towards improved endothelium-dependent microvascular reactivity was observed (P = .07).
  • Significant reductions in inflammatory cytokines (IFNγ, IL-6, IL-12, MIP-1) were noted with linagliptin compared to placebo.

Conclusions:

  • Linagliptin appears to improve endothelial and neurovascular microvascular function in type 2 diabetes patients.
  • Treatment with linagliptin is associated with reduced systemic inflammation markers.
  • No significant effects were observed on mitochondrial function, macrovascular function, or endothelial progenitor cells.